Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Piani

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.
Multiple Sclerosis and Related Disorders|August 1, 2025
Lost in translation: rethinking animal models of progressive MS (an industry perspective)Florian Von Raison, Paola Zaratin, Martin Stangel, et al.
Journal of Clinical Medicine|February 26, 2025
Donor Heart Preservation for Heart Transplantation: Single-Center Experience with Three Different TechniquesAndrea Lechiancole, Gregorio Gliozzi, Sandro Sponga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.
Clinical Transplantation|February 24, 2023
The impact of the distance between patient residency and heart transplant center on outcomes after heart transplantationAndrea Lechiancole, Veronica Ferrara, Sandro Sponga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 9, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trialDouglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, et al.
Journal of Medical Internet Research|October 6, 2021
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based SurveyTjalf Ziemssen, Gavin Giovannoni, Enrique Alvarez, et al.
Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 20, 2025
Oral Semaglutide as an Opportunity for an Appropriate Therapeutic Switch in People with Type 2 Diabetes: A Delphi ConsensusMatteo Bruglia, Francesca Cardini, Raffaella Di Luzio, et al.
Journal of Cardiovascular Development and Disease|June 25, 2026
Outcome After Surgery for Type A Intramural HematomaFausto Biancari, Angelo M Dell'Aquila, Timo Mäkikallio, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 18, 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosisBruce Ac Cree, Baldur Magnusson, Nicolas Rouyrre, et al.
Multiple Sclerosis and Related Disorders|August 1, 2025
Lost in translation: rethinking animal models of progressive MS (an industry perspective)Florian Von Raison, Paola Zaratin, Martin Stangel, et al.
Journal of Clinical Medicine|February 26, 2025
Donor Heart Preservation for Heart Transplantation: Single-Center Experience with Three Different TechniquesAndrea Lechiancole, Gregorio Gliozzi, Sandro Sponga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2022
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 yearsBruce Ac Cree, Douglas L Arnold, Robert J Fox, et al.
Clinical Transplantation|February 24, 2023
The impact of the distance between patient residency and heart transplant center on outcomes after heart transplantationAndrea Lechiancole, Veronica Ferrara, Sandro Sponga, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 9, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trialDouglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, et al.
Journal of Medical Internet Research|October 6, 2021
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based SurveyTjalf Ziemssen, Gavin Giovannoni, Enrique Alvarez, et al.
Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 20, 2025
Oral Semaglutide as an Opportunity for an Appropriate Therapeutic Switch in People with Type 2 Diabetes: A Delphi ConsensusMatteo Bruglia, Francesca Cardini, Raffaella Di Luzio, et al.
Journal of Cardiovascular Development and Disease|June 25, 2026
Outcome After Surgery for Type A Intramural HematomaFausto Biancari, Angelo M Dell'Aquila, Timo Mäkikallio, et al.
Pageof 7